ArticleBritish journal of clinical pharmacology2022

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.

Wei Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.